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Objective: To examine a panel of 28 biomarkers for prediction of cardiovascular disease (CVD) and non-CVD
mortality in a population-based cohort of men.
Methods: Starting in 1979, middle-aged men in Caerphilly underwent detailed medical examination. Subse-
quently 2171 men were re-examined during 1989–1993, and fasting blood samples obtained from 1911 men
(88%). Fibrinogen, viscosity and white cell count (WCC), routine biochemistry tests and lipids were analysed
using fresh samples. Stored aliquots were later analysed for novel biomarkers. Statistical analysis of CVD and
non-CVD mortality follow-up used competing risk Cox regression models with biomarkers in thirds tested at
the 1% signiﬁcance level after covariate adjustment.
Results: During an average of 15.4 years follow-up, troponin (subhazard ratio per third 1.71, 95% CI 1.46–1.99) and
B-natriuretic peptide (BNP) (subhazard ratio per third 1.54, 95%CI 1.34–1.78) showed strong trendswith CVDdeath
but not with non-CVD death. WCC and ﬁbrinogen showed similar weaker ﬁndings. Plasma viscosity, growth differ-
entiation factor 15 (GDF-15) and interleukin-6 (IL-6) were associated positivelywith both CVD death and non-CVD
death while total cholesterol was associated positively with CVD death but negatively with non-CVD death. C-
reactive protein (C-RP), alkaline phosphatase, gamma-glutamyltransferase (GGT), retinol binding protein 4 (RBP-
4) and vitamin B6 were signiﬁcantly associated only with non-CVD death, the last two negatively. Troponin, BNP
and IL-6 showed evidence of diminishing associations with CVD mortality through follow-up.
Conclusion: Biomarkers for cardiac necrosis were strong, speciﬁc predictors of CVD mortality while many
inﬂammatory markers were equally predictive of non-CVD mortality.© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There is increasing evidence that coagulation and inﬂammatory
factors play an important role in the pathogenesis of cardiovascular
diseases (CVD), and this appears to be largely initiated and progressed
by atherothrombotic mechanisms [1]. Coagulation factors, which
include key markers of individual components of the coagulation cas-
cade and inﬂammatory markers, have been extensively investigated in
many cohort studies, which included the Caerphilly Prospective Study
(CaPS) [2], in relation to acute coronary and stroke outcomes. Eighteentitute of Clinical Science Block B,
venor Road, Belfast BT12 6BJ, UK.
land Ltd. This is an open access articlinﬂammatory and haemostatic markers [3] have previously been inves-
tigated in an earlier phase of this study.
Other pathways have also been linkedwith risk of CVD. These include
the following: markers of cardiac necrosis (troponins) and vascular
function (natriuretic peptides) [4], which are routinely used in clinical
diagnostic practice; markers of the acute phase response (to infection),
for example ﬁbrinogen, viscosity and WCC [5], C-reactive protein
[6],and IL-6 [3]; markers of leukocyte activation, pregnancy associated
protein A (PAPP-A) [7,8], and growth differentiation factor (GDF-15)
[9,10]; markers of endothelial function, such as the cellular adhesion
molecules, which are expressed on the surface of vascular endothelial
cells, e.g. vascular cell adhesion molecule-1 (VCAM-1) and endothelial-
leucocyte adhesion molecule-1 (E-selectin) [11,12]; markers of insulin
resistance e.g. glucose, retinol binding protein 4 (RBP-4) [13,14], ande under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ine, vitamin B6 [18,19], which has a role in the metabolism of homocys-
teine. Liver enzymes, such as gamma-glutamyltransferase (GGT), have
also been shown to be independently associated with the risk of CVD
in the general population [20,21].
Few studies have investigated the role of CVD biomarkers in the pre-
diction of non-CVD mortality, but recently the Atherosclerosis Risk in
the Communities (ARIC) study reported that troponin, NT-pro-BNP
and C-reactive protein were associated with risk of CVD, and also
some non-CVD causes [22]. In this report we examine whether a panel
of biomarkers predicts CVD or non-CVD mortality in a long-term
follow-up of men recruited from the general population of the town of
Caerphilly in Wales, UK.
2. Methods
2.1. Study population
CaPS was established in 1979 when men aged 45 to 59 years from the general
population of this South Wales town and its surrounding villages were recruited; 89% of
the eligible population was examined and the cohort was re-examined at approximately
5 yearly intervals. Men were invited to attend an afternoon or evening clinic at which
informed consent and a detailed medical and lifestyle history were obtained, the London
School of Hygiene and Tropical Medicine (LSHTM) chest pain questionnaire was adminis-
tered, a full 12-lead electrocardiogram (ECG) was recorded, and weight and blood
pressure were measured. This report is based on the second follow-up examination of
the men (phase 3) in the period 1989–1993 when the men were predominantly aged
55–69 years. 2171 men were examined, and a fasting blood sample was obtained subse-
quently from 1911 men (88%). All men gave written informed consent. This project was
approved according to the guidelines of the UK National Research Ethics Service by the
South East Wales Research Ethics Committee in July 2009 (reference 09/WSE04/32).
2.2. Blood collection, storage, and analysis
At a separate appointment, shortly after the clinical examination, a venous blood
sample was collected from each man after an overnight fast. Fresh samples were
transported to Frenchay Hospital, Bristol for measurement of ﬁbrinogen, viscosity and
WCC as described previously [5]. Similarly routine biochemistry tests and lipids were
analysed at the University Hospital of Wales, Cardiff. Other aliquots were taken and
plasma or serum were separated within one hour and stored at −20 °C for up to 6 h
and then at−70 °C until laboratory analysis in 2010–13.
2.3. Biomarker assays
Assays for high-sensitivity troponin, B-type natriuretic peptide, C-reactive protein,
GDF-15, cystatin-C, creatinine, ferritin and lipoprotein-a (Lp-a) were performed in the
Mainz Biomarker laboratory as described elsewhere [23]. VCAM-1, E-selectin and IL-6
were assayed in Glasgow using commercial enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Abingdon, UK). PAPP-A (Demeditec Diagnostics, Kiel,
Germany) RBP-4 (R&D Systems, Abingdon, UK), fetuin-A (BioVendor Laboratorni
Medicina, Brno, Czech Republic), and IL-6 receptor (R&D Systems, Abingdon, UK) were
assayed in Belfast using commercial ELISAs, and vitamin B6 was measured using high
performance liquid chromatography (HPLC) by the method of Reynolds and Brain [24].
2.4. Follow-up
The men have been followed for mortality through ﬂagging by the Health and Social
Care Information Centre (HSCIC)with follow-up until 28th February 2012. The underlying
cause of death coded from the death certiﬁcate was used. CVD deaths were deﬁned as
deaths from circulatory causes (ICD-9: 410–438 and 441 or ICD-10: I11, I20–I25, I42,
I50–I51, I60–I69, I71 and I73), Non-CVD deaths were predominantly from cancers (50%)
and from respiratory disease (22%). Accidental and violent deaths accounted for only 3%
of non-CVD deaths.
2.5. Statistical analysis
1773 men had complete data on all relevant covariates and form the basis for the
analysis. The majority of biomarkers showed skewed distributions and small numbers of
men had results below a lower limit of detection for some biomarker assays. Biomarker
results were therefore summarized using median and interquartile ranges and compared
between subgroups using the Mann–Whitney U test. Biomarker distributions were
divided into thirds by sample tertiles for further analysis.
Since many of the assays included in this report are only recently available, up to 30
duplicate serumor plasma samples blinded to eachparticipating laboratorywere included
to assess repeatability. For two biomarkers assayed in Belfast pilot data indicated that the
chosen ELISA kits offered poor reproducibility and another manufacturer's kits were used
instead. Coefﬁcients of variation, representing a combination of inter- and intra-runvariation, were calculated. As assay variation was observed to increase in proportion to
biomarker levels, pairs of biomarker readings were used to derive coefﬁcients of variation
whichwere then averaged across the pairs to give a single summary value. The end points
used for this analysis were CVD death (n = 376) which included death from IHD (n =
265), stroke (n=68), CHF (n=7), aortic aneurysm (n=27) and other circulatory causes
(n = 9). Men with evidence of IHD at baseline or a history of stroke were classiﬁed as
having prior CVD (n= 667) and these menwere retained in the analysis with a covariate
representing prior CVD included in the regression models. A competing risk Cox propor-
tional hazards regression model [25] was used to estimate subhazard ratios (SHRs) for
biomarker variables for each of CVD death and non-CVD death, with the other taken as
a competing risk in the analysis. This approach models cumulative incidence functions
rather than cause-speciﬁc hazard functions and, as has been pointed out in a cardiological
context, is the more appropriate approach when the focus is on prognosis and medical
decisionmaking [26]. Tests for linear trend in the SHRs across the thirds of each biomarker
were obtained together with tests for deviation from linearity across the thirds. An
interaction term between prior CVD and each categorised biomarker was added to each
model to test for evidence that the biomarker was more (or less) predictive in those
with prior CVD than those without prior CVD. A time-dependent covariate test was used
to investigate the subhazard proportionality assumption which speciﬁes that there is no
change in the subhazard ratio with time. A signiﬁcant interaction between a categorised
biomarker and time in the Cox model provided evidence of failure of the proportional
subhazard assumption.
Initial analyses were adjusted only for age (not shown). Subsequent analyses added
the following conventional risk factors as potential confounders: smoking (never/past/
current), diabetes (yes/no), systolic blood pressure, total cholesterol, total triglycerides
(logarithmically transformed), body mass index, history of cardiovascular disease (yes/
no) and family history of CHD before 55 years of age (yes/no).
To reduce the risk of type 1 errors arising in the multiple testing, the 1% signiﬁcance
level was employed for all tests. Analyses were performed using SPSS version 20 (IBM
Corp., Armonk, NY, USA) and Stata release 12 (StataCorp, College Station, TX, USA).
3. Results
The mean period of follow-up for the 1773 men was 15.4 years
(range 0.1–22.3 years) with a total of 27,296 person-years.
Table 1 shows the median values (and interquartile range) in those
men who were alive at the end of follow-up in 2012, in men who had
died fromCVD causes, and in thosewho had died fromnon-CVD causes.
Signiﬁcance values of P b 0.01 and P b 0.001 comparingmedian values in
subjects who died of either CVD or of non-CVD causes with those alive
at follow-up are also shown.
Thirteen biomarkers show signiﬁcantly elevated levels in men who
had subsequently died of CVD and three show signiﬁcantly reduced
levels. Fourteen show signiﬁcant elevations in men who had died of
non-CVD causes and three show signiﬁcant reductions. Vitamin B6
shows signiﬁcantly lower levels in those who died of both CVD and
non-CVD causes, while VCAM and glutamate dehydrogenase show
signiﬁcantly lower levels only in men dying of CVD and cholesterol
and RBP-4 show signiﬁcantly lower levels only in men dying of non-
CVD.
Table 2 shows the SHRs (with 95% conﬁdence intervals) associated
with a one-step increase across the thirds of distribution for each
biomarker. Biomarkers are arranged in descending order of SHR for
cardiovascular disease indicating the strength of their relationships
with risk of death from CVD. SHRs which differ signiﬁcantly from one
(P b 0.01) are shown in bold type. The ﬁnal column of Table 2 shows
P values comparing these SHRs for CVD and non-CVD mortality.
Troponin and BNP each show a strong trend with risk of CVD death
which is not shown with risk of death from non-CVD causes. Total cho-
lesterol also shows an increased risk of CVD death while showing a
strongly negative association with non-CVD mortality. Plasma viscosity,
WCC, GDF-15, IL-6, and ﬁbrinogen also show signiﬁcant trends with
risk of CVD death. Plasma viscosity, IL-6 and (GDF-15) were also signiﬁ-
cantly associated with risk of non-CVD death.
In addition to Troponin and BNP, C-reactive protein, alkaline
phosphatase and GGT, all show signiﬁcant positive relationships with
non-CVD mortality (higher levels associated with increased risk)
while total cholesterol, RBP-4 and vitamin B6 show signiﬁcant negative
associations (higher levels associated with reduced risk).
An interaction between prior CVD and each biomarker was included
in themodel butwas found to be signiﬁcant (P b 0.01) only for E-selectin
Table 1
Median (inter-quartile range) values of biomarkers in men alive at follow-up and in men dying from CVD and from non-CVD causes.
Biomarker CVa Alive Dead — CVD cause Dead — non-CVD cause
n Median (Inter quartile range) n Median (Inter quartile range) n Median (Inter quartile range)
Cardiac and vascular
Troponin (pg/mL) 13% 759 5.50 (4.50–6.90) 360 7.55⁎⁎ (5.73–11.08) 572 6.05⁎⁎ (4.70–7.90)
BNP (pg/mL) 13% 762 20.0 (12.8–31.6) 355 34.3⁎⁎ (19.3–66.0) 564 24.5⁎⁎ (15.4–40.9)
Inﬂammatory
C-RP (mg/L) 4% 760 1.89 (1.07–3.74) 363 3.28⁎⁎ (1.55–6.57) 572 2.99⁎⁎ (1.39–5.91)
IL-6 (pg/mL) 17% 762 1.86 (1.28–2.70) 363 2.65⁎⁎ (1.73–3.83) 573 2.72⁎⁎ (1.89–4.10)
IL-6 receptor (ng/mL) 21% 760 37.9 (30.9–45.3) 363 39.9 (31.8–47.1) 575 38.6 (30.5–45.8)
Lipids
Cholesterol (mmol/L) 1% 796 6.20 (5.60–6.90) 376 6.40 (5.60–7.18) 601 6.00⁎⁎ (5.30–6.80)
Triglyceride (mmol/L) 3% 796 1.60 (1.20–2.40) 376 1.70 (1.20–2.40) 601 1.50 (1.10–2.20)
Lp-a (mg/dL) 27% 755 7.70 (3.60–22.50) 363 8.60 (3.30–21.80) 571 7.80 (3.40–21.50)
Adhesion molecules
VCAM (ng/mL) 8% 761 1259 (1131–1412) 362 1127⁎⁎ (1154–1530) 574 1299⁎⁎ (1170–1479)
E-selectin (ng/mL) 11% 762 25.2 (18.7–32.8) 362 28.2⁎⁎ (20.4–36.6) 574 27.0⁎⁎ (20.1–35.9)
Liver function
Alkaline phosphatase (IU/L) 1% 793 80.0 (68.0–96.0) 376 89.5⁎⁎ (73.3–109.0) 593 90.0⁎⁎ (75.0–111.0)
Aspartate transaminase (IU/L) 6% 791 22.0 (18.0–26.0) 375 21.0 (17.0–25.0) 587 22.0 (18.0–27.0)
Alanine transaminase (IU/L) 5% 794 22.0 (17.0–29.0) 376 21.0 (16.0–27.0) 595 21.0 (17.0–28.0)
Gamma-GT (IU/L) 4% 796 28.5 (20.0–41.0) 376 29.0 (21.0–45.8) 601 31.0⁎ (22.0–47.5)
Glutamate dehydrogenase (IU/L) 25% 356 2.40 (1.30–3.60) 209 1.90⁎ (0.99–3.10) 289 2.10 (1.30–3.35)
Acute phase
White cell count (×109/L) 4% 792 5.83 (5.02–6.87) 373 6.65⁎⁎ (5.42–7.85) 594 6.31⁎⁎ (5.24–7.50)
Viscosity (mPa/s) 1% 790 1.67 (1.62–1.73) 362 1.72⁎⁎ (1.66–1.78) 593 1.70⁎⁎ (1.62–1.78)
Fibrinogen (g/L) 5% 786 3.9 (3.5–4.5) 368 4.2⁎⁎ (3.7–4.9) 591 4.2⁎⁎ (3.6–4.7)
Ferritin (ng/mL) 8% 759 114 (67–198) 360 111 (63–185) 573 117 (61–206)
Leukocyte activation
GDF-15 (pg/mL) 10% 762 618 (492–787) 363 803⁎⁎ (619–1051) 574 819⁎⁎ (633–1082)
PAPP-A (ng/mL) 11% 761 7.10 (5.25–9.19) 363 7.65⁎ (5.57–9.96) 573 7.20 (5.34–9.67)
Renal function
Cystatin-C (mg/L) 2% 760 0.82 (0.74–0.90) 363 0.89⁎⁎ (0.79–0.98) 572 0.86⁎⁎ (0.79–0.98)
Creatinine (mg/dL) 1% 756 0.94 (0.86–1.03) 363 0.93 (0.83–1.05) 571 0.93 (0.85–1.03)
Insulin resistance
Glucose (mmol/L) 6% 794 5.3 (4.9–5.7) 376 5.4⁎⁎ (5.0–6.1) 596 5.3⁎ (5.0–5.9)
Retinol binding protein 4 (mg/L) 18% 760 32.1 (26.9–38.9) 363 31.1 (25.4–37.8) 574 29.9⁎⁎ (24.6–36.2)
Fetuin-A (mg/L) 20% 760 258 (220–305) 363 259 (223–310) 573 259 (220–307)
Others
Uric acid (mg/L) 4% 795 34.0 (29.0–39.0) 376 34.0 (29.0–40.0) 601 34.0 (29.0–39.0)
Vitamin B6 (nmol/L) 18% 763 42.8 (31.9–57.8) 353 36.2⁎⁎ (27.0–50.0) 569 36.1⁎⁎ (26.7–49.2)
a Coefﬁcient of variation for reliability from blinded split samples.
⁎ P b 0.01, compared to the Alive group.
⁎⁎ P b 0.001, compared to the Alive group.
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showed that overall E-selectin was not associated with a signiﬁcant
increase in CVD mortality risk, with a SHR of 1.15, 95% CI 0.99–1.32, it
appeared that there was a signiﬁcant excess risk (SHR 1.35, 95% CI
1.12–1.64) for the subgroup with prior CVD, but no signiﬁcant excess
risk in the subgroup without prior CVD (SHR 0.94, 95% CI 0.77–1.15).
A time dependent covariate analysis was used to check for evidence
that the SHRs changed with the length of follow-up. Troponin, BNP and
total cholesterol showed evidence of a stronger relationship with CVD
mortality during the earlier years of follow-up (P b 0.01, Table 2,
footnote a). These results are also illustrated in Fig. 1.
At time zero troponin shows an estimated SHR of 2.96 reducing to
1.42 by 15 years. IL-6 shows an initial SHR estimate of 1.93 reducing
to 1.05 by 15 years. BNPhas an estimated SHRof 2.44 at time zero falling
to 1.31 by 15 years.
Cystatin-C and aspartate transaminase showed evidence of a non-
linear relationship with CVD mortality (Table 2, footnote b). For both
these biomarkers the lowest risk occurred in the middle third of the
distribution of the biomarker. Our range of biomarkers showed evi-
dence of neither time-dependency nor non-linearity in the relationship
with non-CVD mortality.4. Discussion
In this analysis we have examined the predictive value for both CVD
and non-CVDmortality of a number of biomarkers from a range of pos-
sible pathological pathways after adjustment for conventional risk fac-
tors. Our list is not exhaustive but only a few biomarkers were
omitted which show a consistent relationship with risk of CVD (e.g.
HDL-cholesterol). We ﬁnd that only the markers for cardiac necrosis
and vascular function show a strong and speciﬁc relationship with
CVD mortality, with the cell adhesion molecule VCAM and the protein
PAPP-A each showing a stronger relationship with CVD than with
non-CVD, but not achieving statistical signiﬁcance.
Although many biomarkers have been investigated as potential
markers of CVD, few have been found to usefully add to the clinical pre-
diction of CVD [27]. However, recent large cohort studies have reported
the role of troponins (particularly high-sensitivity troponins) [4,23,28]
and the cardiac peptides BNP and NT-pro BNP [29] as important novel
biomarkers for the prediction of CVD risk in the general middle-aged
population. Both troponins and cardiac peptides add modestly to the
risk of a CVD event in two European cohorts [4] and in a cohort from
the USA [22] after adjustment for conventional risk factors. The period
Table 2
Subhazard ratios (95% CI) for CVD and non-CVD mortality per third of each biomarker
distribution.
Biomarker CVD mortality
subhazard ratio
(95% CI)
Non-CVD mortality
subhazard ratio
(95% CI)
P (CVD
versus
non-CVD)
Troponin 1.71a (1.46–1.99)⁎⁎ 1.00a (0.89–1.11) b0.001
BNP 1.54a (1.34–1.78)⁎⁎ 0.99 (0.89–1.10) b0.001
Plasma viscosity 1.30 (1.13–1.50)⁎⁎ 1.20 (1.08–1.34)⁎⁎ 0.49
White cell count 1.28 (1.11–1.48)⁎⁎ 1.07 (0.96–1.19) 0.10
GDF-15 1.25 (1.07–1.45)⁎ 1.35 (1.20–1.53)⁎⁎ 0.53
IL-6 1.24a (1.08–1.43)⁎ 1.38 (1.24–1.54)⁎⁎ 0.38
Total cholesterol 1.20 (1.05–1.37)⁎ 0.81 (0.72–0.90)⁎⁎ b0.001
Fibrinogen 1.19 (1.05–1.36)⁎ 1.08 (0.98–1.20) 0.32
VCAM 1.19 (1.03–1.36) 1.01 (0.91–1.12) 0.10
Cystatin-C 1.19b (1.02–1.38) 1.09 (0.98–1.21) 0.43
PAPP-A 1.16 (1.01–1.32) 0.97 (0.87–1.08) 0.07
E-selectin 1.15c (0.99–1.32) 1.12 (1.01–1.24) 0.81
C-RP 1.12 (0.98–1.29) 1.22 (1.09–1.36)⁎⁎ 0.42
Alkaline phosphatase 1.09 (0.96–1.24) 1.27 (1.14–1.41)⁎⁎ 0.13
Glucose 1.09 (0.95–1.25) 1.13 (1.02–1.26) 0.70
Triglycerides 1.07 (0.93–1.22) 1.00 (0.90–1.11) 0.46
Uric acid 1.05 (0.91–1.21) 1.11 (0.99–1.23) 0.61
Fetuin-A 1.04 (0.91–1.18) 1.09 (0.98–1.21) 0.58
IL-6 receptor 1.02 (0.90–1.16) 1.00 (0.91–1.11) 0.85
Lp-a 0.99 (0.87–1.13) 1.01 (0.91–1.12) 0.82
GGT 0.98 (0.84–1.13) 1.24 (1.11–1.38)⁎⁎ 0.02
RBP-4 0.95 (0.83–1.09) 0.85 (0.77–0.95)⁎ 0.20
Vitamin B6 0.95 (0.83–1.09) 0.83 (0.75–0.93)⁎ 0.10
Ferritin 0.93 (0.81–1.06) 1.05 (0.95–1.17) 0.13
Alanine transaminase 0.92 (0.81–1.06) 1.07 (0.96–1.19) 0.09
Creatinine 0.90 (0.80–1.03) 1.04 (0.94–1.14) 0.08
Aspartate transaminase 0.89b (0.77–1.02) 1.10 (0.99–1.21) 0.01
Glutamate
dehydrogenase
0.84 (0.70–1.01) 1.06 (0.92–1.23) 0.03
a Evidence of departure from proportional subhazards assumption (P b 0.01).
b Evidence of non-linearity in the relationship between biomarker and mortality
(P b 0.01).
c Evidence of biomarker interaction with prior CVD (P b 0.01).
⁎ P b 0.01.
⁎⁎ P b 0.001.
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present study (mean 15 years). Our results conﬁrm these ﬁndings but
also show that the risk is largest at the time of the initial examination
declining substantially with the passage of time, but still showing a
doubling of the risk per incremental third of the distribution by
15 years (Fig. 1).Fig. 1. Estimated subhazard ratios for risk of cardiovascular death across thirds of the bio-
marker distributions of troponin, BNP, and IL-6 at different time points during follow-up.Subjects with prior CVD were not excluded from our analysis. The
importance of using competing risk approach when appropriate has
been emphasised [26], but unfortunately our competing risk software
did not accommodate stratiﬁcation, which is our preferred approach
to incorporating men with prior CVD in the regression model [2]. How-
ever, in the less appropriate standard Coxmodel analysis we found little
difference between the biomarker hazard ratios obtainedwhether prior
CVD was included in the model as a stratifying factor or as a covariate.
So we chose instead to include prior CVD in the model as a covariate
while checking that prior CVD showed no evidence of interaction with
any biomarker that might indicate that it was more predictive in those
with or in those without prior CVD. Only one such interaction was sig-
niﬁcant suggesting that E-selectinmight be a predictor of CVDmortality
only in those with a prior history of CVD; however some caution is
advised in interpreting this ﬁnding in the light of multiple testing and
the absence of a prior hypothesis.
Adhesion molecules such as E-selectin and VCAM are important in
marking the interaction of leukocytes, platelets and vascular epithelium,
which is an important pathway in the development of atherosclerosis
and plaque formation [30]. In a follow-up study of patients with stable
angina a number of adhesion molecules were measured at baseline,
but only VCAM independently predicted risk of death from IHD adding
to the risk prediction from the classical risk factors and C-reactive
protein [12]. In the present study VCAM had a higher SHR for CVD
than E-selectin, although neither attained statistical signiﬁcance at the
1% level. PAPP-A is a metalloprotein secreted by coronary smooth
muscle which, in a recent meta-analysis of 14 studies, was shown to
be associated with higher mortality rates in prospective studies of pa-
tients with CHD [31]. In the present study PAPP-A is more speciﬁcally
related to risk of CVD (although only at a more lenient 5% signiﬁcance
level) than non-CVD. Cystatin-C has been cited as an emerging risk
marker for CVD [32], but is again only of borderline signiﬁcance for
this outcome in the present report.
Several of the inﬂammatory biomarkers (IL-6, GDF-15, C-RP) and the
liver function tests alkaline phosphatase and GGT show a statistically
signiﬁcant association with risk for non-CVD death which exceeded
the risk for CVD death, although the P values in the ﬁnal column of
Table 2 comparing the SHRs directly were not statistically signiﬁcant.
The association of selected inﬂammatory markers has been noted in
other reports in respect of total mortality (IL-6) [33] and for cause-
speciﬁcmortality (cancers and respiratory disease) (C-reactive protein)
[6,22], but the present report suggests that inﬂammatory markers may
predict non-CVD at least aswell as non-CVD.We examined deaths from
cancers (n= 314) and respiratory deaths (n= 131) as separate causes
of non-CVD mortality but, in a competing risk analysis, none of the
biomarkers showed any tendency toward preferential association with
either of these speciﬁc causes. Other non-CVD causes of death were
too infrequent for separate analysis.
The liver enzymes aspartate and alanine transaminase have been as-
sociated with heart failure cross-sectionally and with the development
of atrial ﬁbrillation, an important cause of heart failure, longitudinally
[34]. In the present study deaths from heart failure are probably
under-represented (but are included under our heading of CVD) since
ICD coding instructions recommend that the underlying cause of
death should be used (which is IHD in more than 50% of our cases of
heart failure that died). In the present report higher levels of these
enzymes were not associated with increased risk of CVD. The enzyme
aspartate transaminase also occurs in cardiacmuscle and, before the in-
troduction of troponins, was used in the diagnosis of acute myocardial
infarction (when it was more commonly known as serum glutamic
oxaloacetic transaminase (SGOT)). The liver enzyme GGT has been
associated with increased risk of stroke (particularly with fatal and
haemorrhagic stroke [35]) and with CVD and total mortality [20] the
present study found no association with CVD but a signiﬁcant associa-
tion with non-CVD. The enzyme alkaline phosphatase occurs in both
liver and bone and raised levels are associated with both CVD and
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which liver enzymes were measured suggested a 60% and a 38%
increase in risk of death between extreme thirds of the distribution
of GGT and alkaline phosphatase, respectively [36]. For aspartate trans-
aminase there was a non-signiﬁcant increase in risk (23%). For alanine
transaminase there was a marked positive association in Asian popula-
tions (43% increase in all-cause mortality) but an 18% decrease in risk in
North American populations.
RBP-4 and vitamin B6 show a signiﬁcant negative association with
risk of non-CVD (higher plasma levels appear to be associated with
decreased risk). RBP-4 does not appear to have been investigated in
large cohort studies but raised levels are associated with the develop-
ment of insulin resistance in mice and with obesity and type 2 diabetes
in human populations [37,38]. Low plasma levels of the active form of
vitamin B6 have been consistently related to the development of colo-
rectal cancer in ﬁve cohort studies [39] in contrast to ﬁndings from
studies of dietary intake. Our ﬁndings support an association between
non-CVD mortality and low levels of plasma vitamin B6, but lack the
statistical power to differentiate the speciﬁc causes of death involved.
Total cholesterol shows a statistically signiﬁcant relationship with
risk of CVD although the association is weaker than six of the other
signiﬁcant biomarkers we studied (Table 2). However, it also shows a
strong and statistically signiﬁcant negative relationship with risk of
non-CVD. This relationship has been shown in other cohort studies
and has been attributed to a metabolic consequence of preclinical
cancer and other non-CVD mortality [40–42]. In an analysis of cancer
deaths (with non-cancer deaths regarded as a competing risk) removal
of deaths in the ﬁrst two years of the study only slightly weakens the
association, with the adjusted SHR per step up the thirds of total choles-
terol changing from 0.83, 95% CI 0.71–0.96 to 0.84, 95% CI 0.71–0.98; re-
moval of deaths in the ﬁrst ﬁve years of the study has a rather greater
impact giving an adjusted SHR of 0.89, 95% CI 0.75–1.06.
This study provides a comprehensive and long-term assessment of a
wide variety of biomarkers enabling us to test both speciﬁcity and time-
dependent effects. However there are several important limitations that
need to be considered. The study is not powered to test for associations
with more speciﬁc causes of death and we have therefore limited our
analysis to a CVD/non-CVD grouping. Our population-based sample
consists only of men so our ﬁndings may not be applicable to women.
Biomarkers were measured only at one time-point; repeat measures
would bemore informative andwould assist in estimation of the effects
of regression dilution bias. Assays were done in historical frozen
samples without regard to possible storage effects, and an analysis
based on fresh samples may show stronger associations. We have only
analysed mortality but it is likely that these biomarkers also predict
non-fatal events though the relative strength may not be the same for
both fatal and non-fatal events.
5. Conclusions
Biomarkers from a range of pathogenic pathways showed signiﬁcant
associations with both CVD and non-CVD mortality. In our panel only
ﬁve proved to be speciﬁc for CVD mortality (troponin, BNP, white cell
count, ﬁbrinogen and total cholesterol). We conﬁrm the relevance of
troponin and BNP asmajor biomarkers in the prediction of cardiovascu-
lar mortality and we found that the estimated SHRs were about twice
the value at baseline of those at 15 years of follow-up. The inﬂammatory
marker IL-6 also showed a weaker association with CVDmortality with
length of follow-up, with no increased risk by 15 years. This was not the
case for its association with non-CVD mortality.
Four out of the eight biomarkers in our panel that showed signiﬁcant
associations with CVD mortality were also signiﬁcant for non-CVD
mortality. An additional ﬁve biomarkers including C-RP, alkaline phos-
phatase and GGT had signiﬁcant positive associations with non-CVD
mortality while low levels of total cholesterol, RBP-4 and plasma vita-
min B6 showed a signiﬁcantly increased risk of non-CVD mortality.Author contributions
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